Osmoprotective Polypeptides for Cell Viability Under Osmotic Stress

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Osmotic stress causes physiological dysfunction by rapid changes in solute concentration, leading to adverse effects on cells, including protein structure alteration, enzyme activity disruption, dehydration, cytoskeleton and nucleus stress, increased reactive oxygen species production, DNA damage, and premature apoptosis, which are linked to inflammatory disorders and tissue damage.

Innovation Solution

Polypeptides with sequences highly identical to SEQ ID NO:1 or SEQ ID NO:2, such as HSP70, exhibit osmoprotective activity, increasing cell viability under osmotic stress by 10-400% when administered in compositions or methods, and can be recombinantly or synthetically produced.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If polypeptides with high sequence identity to HSP70 are used, then osmoprotective activity is improved, but manufacturing complexity increases due to recombinant or synthetic production requirements

Engineering Contradiction:

Improveosmoprotective activityVSAvoidmanufacturing complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent uses recombinant DNA technology to copy the HSP70 gene sequence and express it in host cells, producing polypeptides with high sequence identity (≥95%) to native HSP70. This copying approach enables scalable production while maintaining the osmoprotective activity associated with the native protein sequence

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent systematically varies the amino acid sequence parameters by testing polypeptides with different degrees of sequence identity (95%, 96%, 97%, 98%, 99%, 100%) to HSP70. This parameter optimization identifies the minimum sequence identity threshold required for osmoprotective activity while facilitating simplified manufacturing

Inventive Principle:

Principle #35Parameter changes

2Productivity

If polypeptides are produced recombinantly or synthetically, then production scalability is improved, but production cost increases

Engineering Contradiction:

Improveproduction scalabilityVSAvoidproduction cost

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The patent designs a universal production platform using recombinant expression systems that can produce multiple HSP70 variants with different sequence identities. This multi-functional approach allows a single manufacturing infrastructure to produce various polypeptide versions, reducing overall production costs while maintaining scalability

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent employs transient expression systems and disposable cell lines for recombinant protein production. These temporary, single-use production systems reduce the need for expensive permanent infrastructure while enabling scalable production of HSP70 polypeptides

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS20250304630A1Polypeptides having osmoprotective activity, compositions thereof and uses thereof

Publication Date: 2025.10.02 DELAVIE SCIENCES LLC

AI summary

The technology relates in part to polypeptides having osmoprotective activity and compositions thereof for a variety of uses, including for cosmetic use and for the treatment of disorders, such as inflammatory disorders, which are associated with osmotic stress, or for use as an antioxidant.